Welcome to our dedicated page for CURALEAF HLDGS NEW news (Ticker: CURLD), a resource for investors and traders seeking the latest updates and insights on CURALEAF HLDGS NEW stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CURALEAF HLDGS NEW's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CURALEAF HLDGS NEW's position in the market.
Curaleaf (TSX: CURA, OTCQX: CURLF) reported second quarter 2026 net revenue of $340.1 million, up 10% year-over-year and 5% sequentially. Domestic revenue was $288.7 million and international revenue $51.4 million. Gross profit reached $169.9 million with a 50% gross margin, up 70 basis points year-over-year.
Net income from continuing operations attributable to Curaleaf was $12.5 million, or $0.05 per share. Adjusted EBITDA was $70.1 million, with a 20.6% margin, down 120 basis points year-over-year. For the first half of 2026, net revenue was $664.3 million (+8% year-over-year) and gross profit $327.2 million (49% margin). The company ended the quarter with $107.0 million in cash and $611.5 million of outstanding debt, invested $32.9 million in capex, and repurchased 1.01 million shares for $7.4 million. Operationally, Curaleaf expanded its Florida retail footprint, launched its Dark Heart brand in 11 states, completed the buyout of the remaining 45% of Four20 Pharma, and noted post-quarter approvals for two cannabis medicines in Spain.